Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

MGX

Metagenomi Inc

Dec 11 • 03:15PM ET

3.99

Dollar change -0.20
Percentage change -4.77	%

Healthcare • Biotechnology • USA • NASD

Peers: NTLA CRSP EDIT BEAM VERV PRME DNLI VRTX SGMO ARCT

| Held by: VTI IWM VXF IWO IWN IWC VTWO RSSL VTWG VTWV

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-2.50	Insider Own	49.81%	Shs Outstand	37.43M	Perf Week	114.52%
Market Cap	149.33M	Forward P/E	-	EPS next Y	-2.66	Insider Trans	-0.04%	Shs Float	18.78M	Perf Month	90.91%
Income	-73.95M	PEG	-	EPS next Q	-0.75	Inst Own	25.17%	Short Float	1.45%	Perf Quarter	48.33%
Sales	55.08M	P/S	2.71	EPS this Y	87.64%	Inst Trans	-4.50%	Short Ratio	0.18	Perf Half Y	-34.05%
Book/sh	6.83	P/B	0.58	EPS next Y	-7.39%	ROA	-19.86%	Short Interest	0.27M	Perf Year	-
Cash/sh	7.34	P/C	0.54	EPS next 5Y	-	ROE	-30.34%	52W Range	1.61 - 12.74	Perf YTD	-61.30%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-24.89%	52W High	-68.68%	Beta	-
Dividend TTM	-	Quick Ratio	6.18	Sales past 5Y	3569.20%	Gross Margin	90.66%	52W Low	147.83%	ATR (14)	0.42
Dividend Ex-Date	-	Current Ratio	6.18	EPS Y/Y TTM	-	Oper. Margin	-160.63%	RSI (14)	79.51	Volatility	29.02% 14.04%
Employees	236	Debt/Eq	0.18	Sales Y/Y TTM	-	Profit Margin	-134.27%	Recom	1.29	Target Price	18.40
Option/Short	No / Yes	LT Debt/Eq	0.16	EPS Q/Q	3.46%	Payout	-	Rel Volume	2.26	Prev Close	4.19
Sales Surprise	70.35%	EPS Surprise	34.26%	Sales Q/Q	-6.87%	Earnings	Nov 13 AMC	Avg Volume	1.50M	Price	3.99
SMA20	78.36%	SMA50	89.86%	SMA200	-21.18%	Trades		Volume	3,016,823	Change	-4.77%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-24	Initiated	H.C. Wainwright	Buy	$10
May-02-24	Downgrade	JP Morgan	Overweight → Neutral	$16 → $6
Mar-05-24	Initiated	Wells Fargo	Overweight	$25
Mar-05-24	Initiated	TD Cowen	Outperform
Mar-05-24	Initiated	JP Morgan	Overweight	$16
Mar-05-24	Initiated	Jefferies	Buy	$23
Mar-05-24	Initiated	Chardan Capital Markets	Buy	$21
Mar-05-24	Initiated	BMO Capital Markets	Outperform	$22

Dec-09-24 09:16PM	Metagenomi Presents Updated Preclinical Data in Hemophilia A at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire) +125.41%
Dec-08-24 06:05AM	Jefferies Predicts Up to ~1000% Surge for These 2 Strong Buy Stocks (TipRanks)
Nov-18-24 12:00PM	What Makes Metagenomi (MGX) a New Buy Stock (Zacks)
Nov-13-24 04:37PM	Metagenomi: Q3 Earnings Snapshot (Associated Press Finance) -10.90%
04:05PM	Metagenomi Reports Business Updates and Third Quarter 2024 Financial Results (GlobeNewswire)
04:05PM	Loading…
Nov-05-24 04:05PM	Metagenomi To Present New Preclinical Hemophilia A Data at American Society of Hematology (ASH) 66th Annual Meeting (GlobeNewswire)
Oct-29-24 05:45AM	Metagenomi, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-24-24 08:04AM	Metagenomi Presents Novel, Highly Specific and Efficient Adenine Base Editors for Broad Genome Editing at ESGCT (GlobeNewswire)
Oct-23-24 05:45AM	Investors in Metagenomi, Inc. Should Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Oct-14-24 08:58PM	Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies (GlobeNewswire)
Oct-01-24 03:14PM	Metagenomi, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 25, 2024 to Discuss Your Rights - MGX (PR Newswire)
Sep-19-24 07:15PM	Metagenomi to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -6.84%
Sep-03-24 04:05PM	Metagenomi Announces Preclinical Data for Lead Hemophilia A Program Demonstrating Durable Factor VIII (FVIII) Activity Levels through Twelve Months (GlobeNewswire)
Aug-29-24 07:32PM	Metagenomi Presents AI-Enabled Advancements of SMART Editing Platform at the Cold Spring Harbor Laboratory CRISPR Frontiers Conference (GlobeNewswire)
Aug-28-24 06:10PM	Metagenomi to Participate in Upcoming Investor Conferences (GlobeNewswire) -5.05%
09:00PM	Loading…
Aug-26-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Metagenomi, Target Hospitality, Helios, and LegalZoom and Encourages Investors to Contact the Firm (GlobeNewswire)
Aug-14-24 08:11AM	Metagenomi: Q2 Earnings Snapshot (Associated Press Finance)
08:05AM	Metagenomi Reports Business Updates and Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-12-24 06:29PM	Metagenomi, Inc. (MGX): This New Penny Stock Received a Positive Rating From Street Analysts (Insider Monkey) +10.54%
Aug-05-24 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dril-Quip, LPL Financial, Methode, and Metagenomi and Encourages Investors to Contact the Firm (GlobeNewswire)
Jun-03-24 04:30PM	Is Moderna Inc. (NASDAQ:MRNA) the Top Gene Therapy Stock to Invest in Now? (Insider Monkey)
04:17PM	9 Best Gene Therapy Stocks to Buy Now (Insider Monkey)
May-29-24 04:00PM	Metagenomi to Present at the 2024 Jefferies Global Healthcare Conference (GlobeNewswire)
May-14-24 10:54PM	MGX Stock Earnings: Metagenomi Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:05PM	Metagenomi Presents Data at Scientific Conferences and First Quarter 2024 Financial Results (GlobeNewswire)
May-04-24 10:49AM	Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-02-24 06:04AM	3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire (InvestorPlace) -12.36%
May-01-24 04:00PM	Metagenomi to regain full development rights to its wholly-owned base editing and RIGS systems (GlobeNewswire)
01:53PM	Moderna exits gene editing deal worth up to $3B biobucks, leaving Metagenomi in the spotlight (FierceBiotech.com)
Apr-08-24 08:00AM	Metagenomi to Present at Upcoming Scientific Meetings (GlobeNewswire)
09:16AM	Loading…
Mar-27-24 09:16AM	Metagenomi Reports Business Updates and Full Year 2023 Financial Results (GlobeNewswire)
Feb-29-24 04:30PM	Metagenomi to Participate in the 44th Annual Cowen Healthcare Conference (GlobeNewswire)
Feb-13-24 04:35PM	Metagenomi Announces Closing of Initial Public Offering (GlobeNewswire)
Feb-08-24 10:16PM	Metagenomi Announces Pricing of Initial Public Offering (GlobeNewswire)

Metagenomi, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene edit-ing toolbox, ther-a-peu-tic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Wapnick Pamela	Chief Financial Officer	Dec 05 '24	Sale	1.86	1,559	2,900	61,492	Dec 06 04:24 PM
Wapnick Pamela	Chief Financial Officer	Sep 05 '24	Sale	2.88	6,265	18,043	63,051	Sep 06 05:14 PM
Novo Holdings A/S	10% Owner	Feb 13 '24	Buy	15.00	800,000	12,000,000	1,739,175	Feb 15 08:38 PM
Novo Holdings A/S	10% Owner	Feb 09 '24	Buy	10.25	100,000	1,025,000	100,000	Feb 15 08:38 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGX

Metagenomi Inc

Upgrade your FINVIZ experience